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and the Scleroderma Clinical Trials Consortium
Objective. To evaluate CAT-192, a recombinant
human antibody that neutralizes transforming growth
factor 1 (TGF1), in the treatment of early-stage
diffuse cutaneous systemic sclerosis (dcSSc).
Methods. Patients with SSc duration of <18
months were randomly assigned to the placebo group or
to 1 of 3 CAT-192 treatment groups: 10 mg/kg, 5 mg/kg,
0.5 mg/kg. Infusions were given on day 0 and weeks 6,
12, and 18. The primary objective of this study was to
evaluate the safety, tolerability, and pharmacokinetics
of CAT-192. Secondary outcomes included the modified
Rodnan skin thickness score (MRSS), the Scleroderma
Health Assessment Questionnaire, assessment of organ-
based disease, serum levels of soluble interleukin-2
receptor, collagen propeptides (N propeptide of type I
[PINP] and type III collagen), and tissue levels of
messenger RNA for procollagens I and III and for
TGF1 and TGF2.
Results. Forty-five patients were enrolled. There
was significant morbidity and mortality, including 1
death in the group receiving 0.5 mg/kg of CAT-192 and
3 deaths in the group receiving 5 mg/kg of CAT-192.
There were more adverse events and more serious
adverse events in patients receiving CAT-192 than in
those receiving placebo, although these events were not
more frequent in the high-dose treatment group. The
MRSS improved in all groups during the study, but
there was no evidence of a treatment effect for CAT-192.
Improvement in the MRSS correlated with the disease
duration (r  0.54, P  0.0008). Changes in the PINP
level from baseline correlated with changes in the
MRSS (r  0.37, P  0.027).
Conclusion. We report the first evaluation of a
systemically administered and repeatedly dosed anti-
TGF1 drug. In this pilot study, CAT-192, in doses up to
10 mg/kg, showed no evidence of efficacy. The utility of
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clinical and biochemical outcome measures and the
feasibility of multicenter trials of early dcSSc were
confirmed.
A growing body of evidence indicates a role for
sustained activity of the transforming growth factor 
(TGF) ligand–receptor axis in the pathogenesis of
systemic sclerosis (SSc; scleroderma). Numerous studies
have demonstrated increased expression of TGF1 or
TGF2 in early skin lesions and in lung tissue from
patients with SSc-associated interstitial lung disease,
including immunostaining and in situ hybridization stud-
ies (1,2). Investigators have demonstrated increased
levels of the high-affinity receptors for TGF on ex-
planted SSc fibroblasts and have suggested that, ex vivo,
some of the hallmark biochemical properties of lesional
SSc fibroblasts, such as overproduction of type I colla-
gen, may be reversed or abrogated by neutralizing
antibodies against TGF (3). Indirect evidence support-
ing a role of TGF in the pathogenesis of SSc comes
from a growing body of evidence demonstrating that the
altered biochemical properties of fibroblasts from pa-
tients with SSc are similar to those induced by recombi-
nant TGF in control fibroblasts. For example, up-
regulation of a large number of key TGF-regulated
genes and gene products has been observed (4). Further-
more, in a variety of animal models, TGF-blocking
strategies have been shown to prevent or diminish
fibrosis, including some models of SSc, such as a murine
model of graft-versus-host disease (5).
Current therapies for SSc focus upon treatment
of organ-based manifestations, with successful use of
prostacyclin analogs and endothelin receptor antago-
nists in the treatment of SSc-associated pulmonary
arterial hypertension, angiotensin-converting enzyme in-
hibitors in the treatment of scleroderma renal crisis, and
proton-pump inhibitors in the treatment of gastrointes-
tinal reflux (6). In contrast trials of potential overall
disease-modifying strategies in SSc have been disap-
pointing. Immunomodulatory agents that have been
evaluated include chlorambucil, methotrexate, and ex-
tracorporeal photopheresis (7–9). Putative antifibrotic
or matrix-altering agents tested in SSc have included
D-penicillamine, interferon-, ketanserin, and recombi-
nant human relaxin (10–13).
Confounding aspects of the design of SSc clinical
trials include disease heterogeneity and insufficient,
validated tools for disease assessment in this complex
multisystem disorder (14). Furthermore, several agents
have only been evaluated in relatively late-stage disease,
when spontaneous improvement in the skin score or
relatively stable disease in patients who are not improv-
ing may make it difficult to demonstrate treatment
effects. One alternative strategy is to focus on very
early-stage disease, when deterioration is more likely to
occur without intervention and when prevention of
worsening would be clinically meaningful.
The potentially pivotal role of TGF in the
pathogenesis of SSc, combined with the availability of
fully humanized anti-TGF antibodies of defined spec-
ificity generated by phage-display technology, led us to
consider anti-TGF therapy as a potentially valuable
novel treatment of fibrosis in SSc. We performed a
phase I/II trial of repeated doses of CAT-192, a recom-
binant human antibody against active TGF1, in a
cohort of patients with early-stage diffuse cutaneous SSc
(dcSSc).
PATIENTS AND METHODS
Study design. The primary objective of this study was
to evaluate the safety, tolerability, and pharmacokinetics of
repeated intravenous infusions of CAT-192 (Cambridge Anti-
body Technology, Cambridge, UK) in patients with early-stage
dcSSc. There was an independent Drug Safety Monitoring
Board for the study, and all serious adverse events (SAEs)
were reviewed in real time, with an interim safety analysis. The
secondary objective was to evaluate the potential utility of
various clinical outcomes and biomarkers for future use in a
larger, similarly designed trial. This was an international,
multicenter, randomized, double-blind, placebo-controlled,
dose-ranging, and repeated-dosing study. Blood samples were
taken to evaluate the pharmacokinetics of repeat administra-
tions of CAT-192. The protocol and patient informed consent
forms were approved by Institutional Review Board or Ethics
Committee at each participating site.
Study drug. CAT-192 is a recombinant human mono-
clonal antibody with specific neutralizing activity against active
human TGF1. Subjects were randomized to receive treat-
ment with either placebo or CAT-192 at 1 of 3 doses (0.5
mg/kg, 5 mg/kg, or 10 mg/kg), administered on day 0, week 6,
week 12, and week 18. Each received the same treatment
assignment for all 4 doses and received a test dose of CAT-192
or comparably prepared placebo on day 0 and subsequent visits
according to the study protocol. The study drug was adminis-
tered intravenously over 30 minutes. Subjects were followed
up for evaluation of drug safety and for exploration of clinical
outcomes at 6 months, and a complete safety analysis was
performed at 9 months.
Study subjects. Subjects were recruited from 11 sclero-
derma centers in the US and Europe. Demographic character-
istics of the patients are summarized in Table 1. All patients
fulfilled the American College of Rheumatology (ACR; for-
merly, the American Rheumatism Association) classification
criteria for SSc (15); however, positive findings on tests for
anticentromere antibodies (ACAs) was an exclusion criterion,
given the strong association of ACAs with limited cutaneous
SSc.
To enrich the study cohort for patients in the progres-
sive phase of dcSSc, the following inclusion criteria were
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required for any study subject: enrollment within 18 months of
the onset of their disease (defined as the time from the first
non–Raynaud’s phenomenon manifestation); a modified Rod-
nan skin thickness score (MRSS) between 10 and 28 (inclu-
sive); and evidence of worsening disease by any of the follow-
ing 3 criteria: progression of skin disease to a new skin score
site within the previous 3 months; an increase in the skin score
from 1 to 3 at any skin score location; or the presence of
tendon friction rubs at 3 or more joints (16). The clinical
features of the study cohort are given in Table 2.
Exclusion criteria included the following: a decrease in
the total MRSS of 3 points between the screening and
baseline visits; clinical evidence of another definable connec-
tive tissue or autoimmune disease; exposure to environmental
agents associated with scleroderma-like disease; severe renal
involvement (serum creatinine 2 mg/dl [180 moles/liter]);
actual creatinine clearance of 40 ml/minute; severe protein-
uria (4 by dipstick or 500 mg/24 hours if so measured);
history of scleroderma renal crisis; severe lung involvement,
defined by a forced vital capacity (FVC) of 50% predicted or
a diffusing capacity for carbon monoxide (DLCO) of 40%
predicted or severe dyspnea on exertion; significant heart
disease, defined by the presence of congestive heart failure;
left ventricular ejection fraction 40%, as determined by
echocardiography, or dysrhythmia needing therapy; history of
neoplasia; evidence of retinal detachment in view of the
recognized role of TGF in vitreoretinal repair. Additional
exclusion criteria consisted of any previous treatment with
cyclophosphamide or treatment with any of the following drugs
within 4 weeks of enrollment: cyclosporine, methotrexate,
chlorambucil, azathioprine, mycophenolate mofetil, colchicine,
or D-penicillamine.
Dosages of angiotensin-converting enzyme inhibitors
and/or vasodilators were required to be stable for at least 4
weeks prior to enrollment. Treatment with systemic glucocor-
ticoids at a dosage 10 mg/day of prednisolone or equivalent
was not permitted.
Serum from 100 healthy subjects who were matched
with the SSc patients for age and sex was obtained. Skin
biopsies were performed on 10 healthy volunteers with a
similar sex distribution as the SSc cohort (data not shown).
These samples served as controls.
Clinical outcomes. Clinical assessment of study sub-
jects followed routine clinical practice and standardized clini-
cal trial design by focusing on determining the extent of skin
involvement and the presence of major visceral involvement.
The 17-site MRSS was used, with each site assessed by global
average integer scoring (0–3 scale). Consistent with clinical
trial guidelines (16,17), and to minimize interobserver varia-
tion, all investigators attended skin scoring standardization
sessions, since earlier studies suggest that this reduces interin-
dividual variability in skin scoring (18). Renal function was
determined by serum creatinine and creatinine clearance val-
ues. Pulmonary function testing was performed by standard
techniques and included assessments of FVC, total lung capac-
ity, forced expiratory volume in 1 second, and DLCO.
All subjects completed the Scleroderma Health As-
sessment Questionnaire (HAQ), which is comprised of the
Disability Index (DI) of the HAQ and visual analog scales for
severity assessments of overall SSc, Raynaud’s phenomenon,
lung disease, digital ulcers, and gastrointestinal disease (19,20).
Biomarker evaluation. Biomarkers of collagen turn-
over were evaluated in serum samples and skin biopsy tissues.
Values at baseline and after 6 months were compared. Serum
samples were assayed, and baseline values were compared with
the values in healthy controls (n  100). Skin biopsy samples
(4-mm2) were taken from clinically affected and clinically
unaffected skin (usually, the lower back) of patients with SSc.
Repeat biopsies were taken from sites within 5 cm of the site
of the first procedure. Serum samples and biopsy specimens
were shipped on dry ice to a central laboratory for analysis.
Total RNA was extracted from the skin biopsy tissues and
analyzed by real-time quantitative polymerase chain reaction
(PCR). For comparison with baseline values in the SSc pa-
tients, RNA was extracted from punch biopsies of skin from
healthy volunteers (n  10). Collagen production was assessed
by measuring messenger RNA (mRNA) encoding the 1 chain
of type I and type III procollagen. The mRNA encoding
TGF1 and TGF2 was measured, since these are known to be
up-regulated by TGF1 (21). Serum amino-terminal propep-















Mean  SD 50.2  9.8 48.1  10.1 52.3  12.8 42.8  11.0 48.5  11.1
Median 52.0 49.0 51.0 41.5 49.0
Minimum, maximum 36.0, 65.0 31.0, 64.0 31.0, 76.0 24.0, 63.0 24.0, 76.0
Sex, no. (%)
Male 1 (9) 2 (18) 3 (27) 4 (40) 10 (23)
Female 10 (91) 9 (82) 8 (73) 6 (60) 33 (77)
Race, no. (%)
White 11 (100) 9 (82) 10 (91) 7 (70) 37 (86)
Black – – – 1 (10) 1 (2)
Hispanic – 1 (9) – – 1 (2)
Asian – – 1 (9) 1 (10) 2 (5)
Other – 1 (9) – 1 (10) 2 (5)
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tides of type III collagen (PIIINP) and of type I collagen
(PINP) were measured by commercial radioimmunoassay
(Behringwerke, Marburg, Germany, and Orion Diagnostica,
Helsinki, Finland, respectively). A quantitative immunoassay
was used to determine levels of interleukin-2 receptor (IL-2R;
R&D Systems, Minneapolis, MN).
Adverse events. All AEs were summarized by preferred
term for the number of times reported and the number of
patients who reported that AE in each treatment group and
were tabulated by body system, severity, time to event, and
relationship to study treatment. In addition, SAEs as well as
discontinuations because of SAEs were similarly generated for
each treatment group.
Sample size. The study was designed to evaluate the
safety of CAT-192 and to measure the pharmacokinetics of the
agent, although potential efficacy data were also collected.
These data included exploratory end points that would help
determine variability and utility in a future controlled trial in
early-stage dcSSc. It was initially envisaged that 36 subjects
would be enrolled into the study, but a total of 44 subjects were
randomized. This increased sample size was used in order to
increase the number of evaluable cases at study completion.
Statistical analysis. Analysis of clinical outcomes was
performed on the study population that included all patients
who completed the baseline assessment, received at least 1
infusion of study medication, and had at least 1 postinfusion
assessment. Changes from baseline in the MRSS and biomar-
ker values at weeks 12 and 24 were analyzed using analysis of
variance (ANOVA), and the mean differences, P values, and
95% confidence intervals (95% CIs) are reported. In addition,
the proportion of responders (defined as no change, or any
improvement, in the MRSS) was compared between the active
treatment groups and control groups at weeks 12 and 24 using
the Cochran-Mantel-Haenszel test. These data were analyzed
using Wilcoxon’s rank sum test. Mean or median differences
between each active treatment group and placebo, along with
P values, 95% CIs, and interquartile ranges (IQRs) are pre-
sented. Changes in biomarker values at weeks 12 and 24 were
compared between study subjects and healthy controls using
ANOVA. All data management and statistical analyses were
performed with Oracle (Redwood Shores, CA) and BBN/
Clintrial (Cambridge, MA) software.
RESULTS
Characteristics of the study subjects. Forty-five
patients were enrolled into this trial. Of these, 43
patients received at least 1 infusion of study drug, 31
completed the study, and none were lost to followup.
None had received potential disease-modifying treat-





All patients0.5 mg/kg 5 mg/kg 10 mg/kg
Disease duration, months
No. of patients 10 11 11 10 42
Mean  SD 8.8  7.0 6.0  4.7 7.3  4.6 8.3  5.0 7.6  5.3
Median 5.9 4.6 7.2 9.4 6.4
Minimum, maximum 0.3, 22.5 0.7, 13.8 1.2, 16.7 1.6, 16.2 0.3, 22.5
MRSS
No. of patients 11 11 11 10 43
Mean  SD 23.9  7.1 20.5  4.0 22.1  5.1 22.1  5.8 22.1  5.5
Median 25.0 21.0 23.0 24.0 22.0
Minimum, maximum 11.0, 38.0 14.0, 27.0 14.0, 30.0 13.0, 30.0 11.0, 38.0
Anti–Scl-70, no (%) 1 (9.1) 5 (45.5) 4 (36.4) 2 (20.0) 12 (27.9)
Serum creatinine, moles/liter
No. of patients 11 11 11 10 43
Mean  SD 71.2  12.5 71.0  9.9 77.9  23.4 70.1  17.8 72.6  16.4
Median 70.0 70.0 75.0 68.5 70.0
Minimum, maximum 53.0, 97.0 61.0, 91.0 44.0, 122.0 44.0, 99.0 44.0, 122.0
Creatinine clearance, ml/minute
No. of patients 9 10 8 9 36
Mean  SD 103.1  34.2 104.8  24.0 94.6  35.7 125.8  47.0 107.4  36.1
Median 102.0 105.0 91.1 127.7 103.1
Minimum, maximum 62.2, 148.0 72.0, 138.0 39.5, 156.0 58.9, 200.0 39.5, 200.0
FVC, % predicted
No. of patients 11 11 11 10 43
Mean  SD 92.5  9.7 92.9  17.5 88.8  13.3 88.1  15.6 90.6  13.9
Median 92.0 93.0 92.0 83.5 92.0
Minimum, maximum 75.0, 106.0 60.0, 125.0 69.0, 107.0 69.0, 120.0 60.0, 125.0
DLCO, % predicted
No. of patients 11 11 11 10 43
Mean  SD 72.0  16.4 83.1  22.9 79.0  18.3 69.0  17.3 75.9  19.1
Median 74.0 75.0 76.0 70.5 75.0
Minimum, maximum 47.0, 100.0 52.0, 117.0 55.0, 117.0 37.0, 93.0 37.0, 117.0
* MRSS  modified Rodnan skin thickness score; FVC  forced vital capacity; DLCO  diffusing capacity for carbon monoxide.
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ment prior to study entry. All patients had evidence of
proximal skin sclerosis at study entry, and so, fulfilled
the ACR preliminary criteria for the classification of
SSc. Of the 14 subjects who withdrew (13 in the CAT-
192 group; 1 in the placebo group), the majority (n  9)
did so because of adverse events.
Pharmacokinetics of CAT-192. Serum levels of
CAT-192 were detectable in all 3 active treatment
groups. The half-life of the agent (mean  SEM 24.0 
2.1 days) was comparable across the dosage groups.
Safety and tolerability of CAT-192. Four deaths
were reported during the study, 1 in the group receiving
0.5 mg/kg of CAT-192 and 3 in the group receiving 5
mg/kg. All deaths were attributed to complications of
the underlying disease, and none was considered to be
related to the administration of CAT-192. In the group
receiving 0.5 mg/kg, the patient had progressive skin and
muscle disease and had received 2 infusions of CAT-192.
Treatment was then changed to cyclophosphamide, but
the patient died of cardiac failure despite therapy. In the
group receiving 5 mg/kg, 1 death resulted from progres-
sive skin and gastrointestinal tract disease in the context
of end-stage renal failure following scleroderma renal
crisis. This patient received 1 infusion of CAT-192, but
the drug was withdrawn after renal crisis occurred; this
developed 6 weeks after the study drug infusion and was
considered to be unrelated to the study drug. The second
death in this group resulted from progression of the SSc,
with cardiac and lung involvement. This patient had
received 3 infusions of CAT-192. The third death oc-
curred in a patient who developed progressive pulmo-
nary fibrosis. This patient had received 1 infusion of
CAT-192 and was subsequently treated with intravenous
cyclophosphamide. Despite this treatment, however, the
patient developed respiratory failure and died.
AEs and SAEs were frequent in this study and
are consistent with the predictably high morbidity of
early-stage dcSSc. Overall, there were more AEs and
SAEs in patients receiving CAT-192 than in those
receiving placebo. A total of 19 SAEs occurred in 5
patients receiving 0.5 mg/kg, 15 occurred in 4 receiving 5
mg/kg, and 7 occurred in 2 receiving 10 mg/kg of
CAT-192, and 3 SAEs occurred in 2 patients receiving
placebo. Details of the SAEs are provided in Table 3.
There were a total of 275 unique AEs, including
54 AEs in patients receiving placebo and 75 in those
receiving 0.5 mg/kg, 87 in those receiving 5 mg/kg, and
59 in those receiving 10 mg/kg of CAT-192. All but 1 of
the patients (receiving 0.5 mg/kg of CAT-192) experi-
enced an AE.
The most commonly reported AEs affected the
gastrointestinal, musculoskeletal, respiratory, and skin
systems. This included skin ulceration in all but the
group taking 10 mg/kg of CAT-192. Although more AEs


















No. of patients experiencing an event*
Serious adverse event† 2 5 4 2 11 (34) 13 (30)
Death‡ 0 1 3 0 4 (12.5) 4 (9)
No. of individual serious adverse events
Progression of skin involvement 1 2 3 0 5 6
Gastrointestinal manifestations 0 3 1 2 6 6
Weight loss 0 1 0 0 1 1
Gastrointestinal hemorrhage/anemia 1 2 1 1 4 5
Infusion reaction 0 0 1 0 1 1
Autoantibody response 0 0 0 1 1 1
Constitutional symptoms 0 1 1 2 4 4
Musculoskeletal pain 0 3 0 1 4 4
Cardiac manifestations 0 1 3 0 4 4
Infection 1 0 2 0 2 3
Pulmonary manifestations 0 4 3 0 7 7
Impaired mobility 0 2 0 0 2 2
Total no. of serious adverse events 3 19 15 7 41 44
* Patients often experienced multiple serious adverse events: 41 occurred in 11 patients receiving CAT-192 (34%), and 3 occurred in 2 patients
receiving placebo (18%).
† Defined as life-threatening, causing serious incapacity, or leading to additional hospitalization; or requiring treatment to prevent any of these
outcomes.
‡ See Results for causes of death.
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and SAEs occurred in the active treatment groups, there
was no relationship to the dosage, in that there were
similar numbers of AEs and SAEs in the groups receiv-
ing 0.5 mg/kg and 10 mg/kg, and perhaps more impor-
tantly, the number of patients experiencing an AE or an
SAE was similar for placebo-treated patients and those
in the 10 mg/kg groups, despite apparent differences in
the total number of events. Thirteen patients experi-
enced 30 unique SAEs, most of which appeared to be
related to the underlying dcSSc. None were considered
to be related to the study medication. Many of the events
occurred in the same patient and reflected disease
progression; 2 patients experienced repeated episodes of
gastrointestinal hemorrhage.
Overall, intravenous administration of CAT-192
was well tolerated among the 32 patients who received
the active study drug, with the majority of reported AEs
being mild or moderate in intensity and unrelated to the
treatment. The most common AEs leading to discontin-
uation of therapy were progression of SSc skin disease or
worsening breathlessness, which occurred in 9 patients
(1 taking placebo, 4 taking 5 mg/kg of CAT-192, and 4
taking 10 mg/kg).
Changes in skin scores. Median values for the
MRSS were compared among the 4 treatment groups,
from screening to completion of the assessment period.
The data are summarized in Figure 1. Our results do not
show any evidence of efficacy for CAT-192, since al-
though there was overall improvement in skin sclerosis
during the study, the change in the MRSS appeared to
be independent of treatment group (P  0.49). The
duration of disease at baseline was significantly corre-
lated with the change in skin score between baseline and
6 months (r  0.54, P  0.0008) (Figure 2).
Other outcomes. As expected, there was substan-
tial evidence of functional impairment at baseline in the
study cohort, with mean  SD HAQ DI scores of 1.0 
0.70 (range 0.00–2.60). There were no statistically sig-
nificant differences in HAQ DI scores among any of the
4 treatment subgroups, ranging from 0.80  0.60 in the
group receiving 0.5 mg/kg of CAT-192 to 1.40  0.90 in
the group receiving 5 mg/kg. The mean  SD change
Figure 1. Change in the modified Rodnan skin thickness score
(MRSS) from baseline to month 6 in patients with diffuse cutaneous
systemic sclerosis treated with placebo or with 3 different doses (0.5, 5,
or 10 mg/kg) of CAT-192. A, Individual MRSS changes in each
treatment group. B, Box-and-whisker plot showing overall changes in
MRSS during the study as compared with baseline. Boxes show the
interquartile range. Lines within the boxes show the median. Vertical
lines indicate the range. Circles indicate outliers.
Figure 2. Relationship between change in the modified Rodnan skin
thickness score (MRSS) and disease duration in patients with diffuse
cutaneous systemic sclerosis (dcSSc) treated with placebo or with 3
different doses (0.5, 5, or 10 mg/kg) of CAT-192. There was a highly
statistically significant association between the duration of dcSSc at
baseline and the change observed in the MRSS between baseline and
week 24 of study (r  0.54, P  0.0008). This suggested that disease
duration at baseline was a major determinant of outcome.
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Figure 3. Analysis of biomarkers at baseline in patients with diffuse cutaneous systemic
sclerosis (dcSSc) and in healthy control subjects. A, Serum biomarkers are elevated in
patients with dcSSc as compared with those in age- and sex-matched healthy control
subjects, confirming immunologic activation and fibrillar collagen overproduction. sIL-2R 
soluble interleukin-2 receptor; PINP  N-propeptide of type I collagen; PIIINP 
N-propeptide of type III collagen. B, Expression of mRNA for transforming growth factor
1 (TGF1) and TGF2 is elevated in lesional skin biopsy tissue from patients with dcSSc.
There was also a trend toward elevated expression in biopsy tissue from nonlesional skin as
compared with that in skin biopsy tissue from sex-matched healthy controls. For the
procollagen genes COL1A3 and COL1A1, there were significant elevations in mRNA levels
in both lesional and nonlesional skin from dcSSc patients, although the levels tended to be
greater in lesional skin. Together, these results suggest that gene expression in uninvolved
skin is also altered. This may reflect background genetic susceptibility or subclinical skin
involvement. Values are the mean and SD. P values are versus controls, as determined by
analysis of variance.
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from baseline was 0.15  0.50. The magnitude of change
overall was below the level suggested to be a minimal
clinically significant difference in other rheumatic dis-
eases (20,22).
Analysis of changes in indices of pulmonary
function revealed few changes in any patient. Only 2
patients showed 10% worsening in the FVC over 6
months: one in the group receiving placebo and the
other in the group receiving 0.5 mg/kg of CAT-192. In
contrast, 4 patients in various groups demonstrated at
least a 15% decrease in the DLCO.
There were variable changes in renal function
from the time of screening between the treatment
groups, but these did not appear to reflect the treatment
received. There was 1 confirmed hypertensive renal
crisis, which occurred in a patient receiving 5 mg/kg
of CAT-192 and required hemodialysis. In addition,
there were 3 episodes of new-onset systemic hyperten-
sion without renal impairment, 1 in the group receiving
placebo and 2 in the group receiving 0.5 mg/kg of
CAT-192. Treatment with angiotensin-converting en-
zyme inhibitors was given for all 3 episodes.
Serum levels of biomarkers. The serum biomar-
kers selected for analysis were those that indicated
collagen biosynthesis and immunologic activity. There
were clear differences at baseline in the levels of PINP
(mean  SD 8.5  3.5 g/liter versus 5.1  2.4 g/liter;
P  0.0001) and PIIINP (6.8  6.2 g/liter versus 3.5 
1.1 g/liter; P  0.0001) in the SSc patients versus the
healthy controls. There were changes in the levels of
these propeptides during the study period, but these
changes did not differ between treatment groups. Asso-
ciation with disease duration was not observed.
Serum levels of IL-2R (ng/liter) were much higher
in the patients with SSc (1.8  0.9) than in healthy con-
trol subjects (0.8  0.3; P  0.0001). The scleroderma-
associated autoantibody anti–topoisomerase I did not
change during the treatment period, and no significant
difference between the baseline and end of study levels
of sIL-2R, PIIINP, or PINP was observed in any treat-
ment group. However, when changes in the MRSS were
compared with changes in the various biomarker levels,
only PINP levels showed statistically significant changes
that correlated with the MRSS (r  0.37, P  0.027).
Findings of mRNA analysis of skin biopsy spec-
imens. Real-time quantitative PCR analysis of markers
of fibrosis (COL1A1, COL3A1, TGFB1, and TGFB2)
demonstrated that levels of mRNA for these markers
were increased in affected skin obtained from patients
with SSc, but there was no change during treatment.
There were changes in transcript levels between the time
of screening and completion of the treatment phase of
study, but these were not significantly associated with
changes in the MRSS. There were no significant differ-
ences in transcript levels at the completion of treatment
among the treatment groups. Despite changes in skin
scores that occurred between baseline and the end of the
treatment phase, there was no significant correlation
between skin score changes and changes in the levels of
mRNA for any of the markers of fibrosis that were
examined. Baseline data for the biomarkers examined
are summarized in Figure 3.
DISCUSSION
This study represents an important step in the
development and exploration of the concept of opposing
the action of TGF as a therapeutic intervention for
SSc. There is a large body of indirect evidence implicat-
ing the overexpression of TGF ligand or receptor in the
pathogenesis of SSc (23), and several recent studies have
demonstrated that blocking TGF ligand may abrogate
fibrosis in a number of mouse models (24). In addition,
activation of TGF signaling pathways constitutively in
fibroblasts replicates many of the key histologic and
biochemical features of established SSc (25). In this
context, it is disappointing that our study did not show
any evidence of efficacy for CAT-192. In animal models
of fibrosis, effective prevention of fibrosis has generally
required the blockade of multiple isoforms of TGF,
and this is a potential explanation for the lack of effect
on markers of efficacy in this study. Thus, soluble TGF
receptors that block all active TGF ligand and the
pan-isoform–specific antibody 1D11 are both effective in
blocking fibrosis, as is a polyclonal anti-TGF and a
recombinant latency-associated peptide (26,27). Other
blocking strategies, such as overexpression of Smad7 or
decorin, have also been tested in animal models (28).
Concerns about the safety of CAT-192 reflect the
well-recognized association between defective TGF
signaling and immunologic activation, the antiprolifera-
tive effect of TGF on epithelial cells, and the recogni-
tion that several downstream products in the TGF
signaling cascade may function as tumor-suppressor
genes (29). An additional concern at the outset was
that no human had ever received multiple doses of
CAT-192. With this background, it is appropriate that
a mono-isoform–specific antibody was chosen for initial
evaluation. Such treatment would be predicted to pro-
vide partial blockade of the TGF axis and allow the
evaluation of safety. Interestingly, results of animal
studies suggest that blocking of TGF is relatively safe.
Recent strategies that induce very significant blockade
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in tumor models do not seem to increase the degree of
metastasis (30).
This was primarily a safety and tolerability study.
There were more AEs, SAEs, and deaths in the active
treatment groups than in the placebo treatment group.
This may have been a consequence of CAT-192. How-
ever, multiple events occurred in the same patients with
progressive disease, and when the number of patients in
each subgroup that experienced AEs or SAEs is consid-
ered, a possible relationship to therapy seems much less
likely, particularly since similar numbers of patients in
the placebo and high-dose CAT-192 groups were af-
fected by AEs and SAEs. Nevertheless, the high mortal-
ity rate observed in this study cohort is noteworthy and
is above that seen in other recent trials of dcSSc. This
may reflect the selection of cases with early progressive
disease and the severe cases referred to the specialist
centers that participated in the study. Direct comparison
with other trials is complicated by differences in entry
criteria; for example, the median disease duration was
lower in the present study than in the other trials that
have been published. It is quite possible that a more
complete blockade of the TGF axis might, in turn, be
associated with substantial toxicity.
Robust evaluation of novel therapies in SSc re-
mains a major challenge and is complicated by hetero-
geneity of the disease and the absence of any agents with
proven effectiveness. Previous studies yielding negative
results have hampered the development of validated
assessment tools that are sensitive to change over the
time course of a therapeutic clinical trial. There is
continued interest in this area, and several groups of
investigators have reported guidelines for disease assess-
ment and for the performance of clinical trials
(16,17,31). At present, for a short-term study, the MRSS
remains the most frequently used tool for the assessment
of skin sclerosis. To minimize interobserver variations in
the MRSS, standardization of skin scores was performed
at baseline to ensure that there was consistency among
observers. In addition, wherever possible, the same
observer assessed individual subjects during the study. A
limitation of the MRSS as a trial end point highlighted
by the present study is that even when very early-stage
dcSSc patients are recruited, there is an overall tendency
for the MRSS to improve. This challenges the feasibility
of a “prevention of worsening” study design despite the
success of this trial in targeting and enrolling an early
disease cohort. It suggests that improvement in skin
involvement is not confined to late-stage disease (32).
The HAQ DI data confirm the severe functional
impact of dcSSc. The mean levels of disability are similar
to those reported for other chronic multisystem diseases
that affect hand function, such as rheumatoid arthritis
(33). Changes in the HAQ DI scores did not seem to
depend upon treatment with CAT-192, but in general,
patients with longer disease duration had higher HAQ
DI scores. Renal and lung function test results provided
additional information concerning the impact of dcSSc
in this cohort. However, no changes in these variables
that might be attributed to treatment with CAT-192
were observed.
Serial assessment of lesional and nonlesional
(clinically unaffected) skin biopsy samples represents the
most direct way of assessing changes in scleroderma
patients at a biochemical level. The transcripts selected
for analysis by real-time quantitative PCR included 2
profibrotic cytokines, TGF1 and TGF2, and 2 extra-
cellular matrix molecules, PINP and PIIINP. Elevation
of these cytokines in lesional skin confirms the validity of
these markers. This is one of the few studies to use such
a rigorous biochemical evaluation of treatment effects,
and our results provide validity for this approach. Clear
differences were identified between lesional and nonle-
sional sites as well as between SSc and healthy control
samples. Abnormalities in the samples from nonlesional
sites are consistent with earlier reports that unaffected
skin from patients with SSc is diseased (34); this has
been shown by histologic assessment as well as by
assessment of skin biomechanics (35). Most recently,
gene expression profiling data support this finding (36)
and are perhaps the most relevant comparisons to our
study. In the future, groups of genes or protein profiles
may be defined as biomarkers of bioactivity in SSc
clinical trials, especially early-stage, proof-of-concept
studies where skin scores may not change greatly in a
short time.
The serum biomarkers examined in this study
were selected to demonstrate effects on collagen biosyn-
thesis and immune system activation. The N-terminal
propeptides are cleaved from procollagen molecules
during posttranslational processing and are an index of
newly synthesized collagen. It is interesting that PINP
was the only variable to be associated with changes in
skin scores, adding validity to this outcome measure in
SSc (37). Levels of sIL-2R are increased in condi-
tions associated with immunologic activation (38). Thus,
the increased levels observed in the present study pro-
vide confirmation of immune system activation in early
dcSSc. This is consistent with the presence of T cell
infiltrates in lesional tissues and with the body of evi-
dence pointing toward immunopathogenesis, and it jus-
tifies the use of caution in treating patients with an
antibody to a known immunosuppressive cytokine. The
role of other immunosuppressive factors, such as IL-10,
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in SSc remains to be determined. There was no increase
in sIL-2R levels in any treatment group.
In conclusion, this is the first time that a biologic
agent has been used to specifically target one of the key
candidate factors in the pathogenesis of SSc. Overall,
our findings suggest that early-stage dcSSc can be iden-
tified and targeted and that levels of biomarkers are
abnormal in this group, but the findings do not show
efficacy for CAT-192 in this cohort of patients with SSc.
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